Literature DB >> 22126732

Does overall treatment time impact on survival after whole-brain radiotherapy for brain metastases?

C Nieder1, N H Andratschke, O Spanne, H Geinitz, A L Grosu.   

Abstract

PURPOSE To evaluate whether reduced overall treatment time (OTT), i.e., administration of more than 5 fractions per week, or uncompensated treatment interruption resulting in increased OTT influences survival of patients treated with whole-brain radiotherapy (WBRT) for brain metastases. METHODS Retrospective multi-institutional intention-to-treat study including 233 patients treated with primary WBRT (prescribed dose 10 fractions of 3 Gy; no previous SRS or surgery) administered over 10-38 days. Four groups were studied: OTT 10-11 vs. 12 days, 13-15 or >15 days. RESULTS Fourteen patients (6%) failed to complete WBRT and received 3-9 fractions (median 7). Their median survival was 0.5 months as compared to 3 months in patients who completed WBRT. No significant impact of OTT on survival was found. Median survival was 1.5, 2.9, 3.0 and 3.1 months in the four groups mentioned above. CONCLUSIONS Compensation for unintended treatment interruption is generally recommended but might not always be feasible. Depending on histological tumour type or expected repopulation, prognostic factors and neurological status, it might be acceptable to complete an interrupted course of WBRT without compensation in selected patients. While survival might be largely independent from OTT, it should also be evaluated whether this parameter has any impact on quality of life and duration of palliation.

Entities:  

Mesh:

Year:  2011        PMID: 22126732     DOI: 10.1007/s12094-011-0750-6

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  22 in total

1.  Radiobiological compensation for unintended treatment interruptions during palliative radiotherapy.

Authors:  B Jones; J W Hopewell; R G Dale
Journal:  Br J Radiol       Date:  2007-12       Impact factor: 3.039

2.  A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database.

Authors:  Paul W Sperduto; Brian Berkey; Laurie E Gaspar; Minesh Mehta; Walter Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-10-10       Impact factor: 7.038

3.  Palliative radiotherapy tailored to life expectancy in end-stage cancer patients: reality or myth?

Authors:  Stephan Gripp; Sibylle Mjartan; Edwin Boelke; Reinhardt Willers
Journal:  Cancer       Date:  2010-07-01       Impact factor: 6.860

4.  Presentation, patterns of care, and survival in patients with brain metastases: what has changed in the last 20 years?

Authors:  Carsten Nieder; Oddvar Spanne; Minesh P Mehta; Anca L Grosu; Hans Geinitz
Journal:  Cancer       Date:  2010-12-14       Impact factor: 6.860

5.  Prediction of short survival in patients with brain metastases based on three different scores: a role for 'triple-negative' status?

Authors:  C Nieder; A Pawinski; M Molls
Journal:  Clin Oncol (R Coll Radiol)       Date:  2009-09-16       Impact factor: 4.126

6.  Hypofractionated stereotactic radiotherapy for brain metastases--results from three different dose concepts.

Authors:  Antje Fahrig; Oliver Ganslandt; Ulrike Lambrecht; Gerhard Grabenbauer; Gabriele Kleinert; Rolf Sauer; Klaus Hamm
Journal:  Strahlenther Onkol       Date:  2007-11       Impact factor: 3.621

Review 7.  Current treatment strategies for brain metastasis and complications from therapeutic techniques: a review of current literature.

Authors:  Christopher S Platta; Deepak Khuntia; Minesh P Mehta; John H Suh
Journal:  Am J Clin Oncol       Date:  2010-08       Impact factor: 2.339

8.  Reduction of overall treatment time in patients irradiated for more than three brain metastases.

Authors:  Dirk Rades; Susanne Kieckebusch; Radka Lohynska; Theo Veninga; Lukas J A Stalpers; Juergen Dunst; Steven E Schild
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-08-06       Impact factor: 7.038

Review 9.  The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.

Authors:  Mark E Linskey; David W Andrews; Anthony L Asher; Stuart H Burri; Douglas Kondziolka; Paula D Robinson; Mario Ammirati; Charles S Cobbs; Laurie E Gaspar; Jay S Loeffler; Michael McDermott; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Nina A Paleologos; Roy A Patchell; Timothy C Ryken; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2009-12-04       Impact factor: 4.130

Review 10.  The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.

Authors:  Steven N Kalkanis; Douglas Kondziolka; Laurie E Gaspar; Stuart H Burri; Anthony L Asher; Charles S Cobbs; Mario Ammirati; Paula D Robinson; David W Andrews; Jay S Loeffler; Michael McDermott; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Nina A Paleologos; Roy A Patchell; Timothy C Ryken; Mark E Linskey
Journal:  J Neurooncol       Date:  2009-12-04       Impact factor: 4.130

View more
  1 in total

1.  Stereotactic radiosurgery for brain metastases from malignant melanoma.

Authors:  Sebastian M Christ; Anand Mahadevan; Scott R Floyd; Fred C Lam; Clark C Chen; Eric T Wong; Ekkehard M Kasper
Journal:  Surg Neurol Int       Date:  2015-08-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.